The role of lipids in the pathogenesis of muscle insulin resistance and beta cell failure in type II diabetes and obesity
The DOI matches its Crossref record.
Abstract
This review considers evidence for, and putative mechanisms of, lipid-induced muscle insulin resistance. Acute free fatty acid elevation causes muscle insulin resistance in a few hours, with similar muscle lipid accumulation as accompanies more prolonged high fat diet-induced insulin resistance in rodents. Although causal relations are not as clearcut in chronic human insulin resistant states such as obesity and type 2 diabetes, it is now recognised that muscle lipids also accumulate in these states. The classic Randle glucose-fatty acid cycle is only one of a number of mechanisms by which fatty acids might influence muscle glucose metabolism and insulin action. A key factor is seen to be accumulation of muscle long chain acyl CoAs, which could alter insulin action via several mechanisms including chronic activation of protein kinase C isoforms or ceramide accumulation. These interactions are fundamental to understanding metabolic effects of new insulin "sensitizers", e.g. thiazolidinediones, which alter lipid metabolism and improve muscle insulin sensitivity in insulin resistant states. Recent work has also pointed to a possible role of lipids in beta cell deterioration ("lipotoxicity") associated with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.
Guilherme, A., Virbasius, J. V., Puri, V., & Czech, M. P. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2391 · Cited by 2,292
Mitochondrial dysfunction and type 2 diabetes
Lowell, B. B., & Shulman, G. I. (2005) · Science · doi:10.1126/science.1104343 · Cited by 2,070
Yu, C., Chen, Y., Cline, G. W., Zhang, D., Zong, H., Wang, Y., Bergeron, R., Kim, J. K., Cushman, S. W., Cooney, G. J., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200958200 · Cited by 1,561
Self-citationNguyen, M. T. A., Favelyukis, S., Nguyen, A.-K., Reichart, D., Scott, P. A., Jenn, A., Liu-Bryan, R., Glass, C. K., Neels, J. G., & Olefsky, J. M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706762200 · Cited by 1,035
Ceramides in insulin resistance and lipotoxicity
SUMMERS, S. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2005.11.002 · Cited by 848
Insulin effects in muscle and adipose tissue
Dimitriadis, G., Mitrou, P., Lambadiari, V., Maratou, E., & Raptis, S. A. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70014-6 · Cited by 649
Metabolic Syndrome: A Clinical and Molecular Perspective
Moller, D. E., & Kaufman, K. D. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104751 · Cited by 631
Malonyl-CoA Signaling, Lipid Partitioning, and Glucolipotoxicity
Prentki, M., Joly, E., El-Assaad, W., & Roduit, R. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s405 · Cited by 431
Medina-Gomez, G., Gray, S. L., Yetukuri, L., Shimomura, K., Virtue, S., Campbell, M., Curtis, R. K., Jimenez-Linan, M., Blount, M., Yeo, G. S. H., et al. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030064 · Cited by 430
Nguyen, M. T. A., Satoh, H., Favelyukis, S., Babendure, J. L., Imamura, T., Sbodio, J. I., Zalevsky, J., Dahiyat, B. I., Chi, N.-W., & Olefsky, J. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504611200 · Cited by 411
AMPK regulation of fatty acid metabolism and mitochondrial biogenesis: implications for obesity.
O’Neill, H. M., Holloway, G. P., & Steinberg, G. R. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.06.019 · Cited by 364
Yang, G., Badeanlou, L., Bielawski, J., Roberts, A. J., Hannun, Y. A., & Samad, F. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.91014.2008 · Cited by 295
Gutierrez-Juarez, R. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26991 · Cited by 296
Iglesias, M. A., Ye, J.-M., Frangioudakis, G., Saha, A. K., Tomas, E., Ruderman, N. B., Cooney, G. J., & Kraegen, E. W. (2002) · Diabetes · doi:10.2337/diabetes.51.10.2886 · Cited by 290
“LCACoAs can inhibit the activities of hexokinase (37), pyruvate dehydrogenase, and glycogen synthase (38).”
BackgroundSelf-citationHan, X., Yang, J., Yang, K., Zhao, Z., Abendschein, D. R., & Gross, R. W. (2007) · Biochemistry · doi:10.1021/bi7004015 · Cited by 271
Neschen, S., Morino, K., Hammond, L. E., Zhang, D., Liu, Z.-X., Romanelli, A. J., Cline, G. W., Pongratz, R. L., Zhang, X.-M., Choi, C. S., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.06.006 · Cited by 261
“1992; Griffin et al., 1999; Hegarty et al., 2003; Jucker et al., 1999; Kraegen et al., 2001; Petersen et al., 2004; Samuel et Hepatic pAMPK protein content, pACC protein content, and malonyl-CoA levels are not altered in livers al., 2004; Shulman, 2000; Yu et al., 2002).”
BackgroundMuscle Oxidative Capacity Is a Better Predictor of Insulin Sensitivity than Lipid Status
Bruce, C. R., Anderson, M. J., Carey, A. L., Newman, D. G., Bonen, A., Kriketos, A. D., Cooney, G. J., & Hawley, J. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030791 · Cited by 234
Self-citationUkropcova, B., Sereda, O., de Jonge, L., Bogacka, I., Nguyen, T., Xie, H., Bray, G. A., & Smith, S. R. (2007) · Diabetes · doi:10.2337/db06-0521 · Cited by 165
Metadata
- Authors
- Kraegen, E., Cooney, G., Ye, J.-M., Thompson, A., & Furler, S.
- Venue
- Experimental and Clinical Endocrinology & Diabetes
- Publisher
- Georg Thieme Verlag KG
- Published
- 2001-11-23
- Volume
- 109
- Issue
- Suppl 2
- Pages
- S189-S201
- ISSN
- 0947-7349 (ISSN-L)
- 1439-3646
- OpenAlex
- W2058661481
- Cited by
- 130
- References
- 0
- FWCI
- 7.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.